{
    "nct_id": "NCT04129216",
    "official_title": "The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer",
    "inclusion_criteria": "Inclusion criteria\n\n* Treatment-na√Øve, histologically confirmed invasive ductal breast cancer between stages 1 to 3.\n* Co-enrollment in the FLEX Registry\n* Estrogen Receptor Positive (ER+) Progesterone Receptor Positive (PR+) confirmed hormone receptor status measured by immunohistochemistry (IHC)\n* Patients should understand patients' condition and be able to give informed consent to participate\n\nExclusion criteria\n\n* History of hormonal therapy, chemotherapy, radiation therapy, or novel therapy to treat the current breast cancer.\n* Allergic reactions/hypersensitivity to tamoxifen, letrozole, or exemestane or any of the ingredients of these drugs.\n* Any contraindication to hormonal therapy, such as history of thromboembolic disease or uterine cancer.\n* Patients without invasive disease (stage 0)\n* Patients with metastatic breast cancer(stageIV)\n* Patients that are Human Epidermal Growth Factor 2+(HER2+) by IHC/Fluorescence in situ hybridization (FISH).\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}